- GlobeNewswire•9 days agoInsmed Announces Publication of Phase 2 Study of ARIKAYCE in Treatment-Refractory Nontuberculous Mycobacterial Lung Disease
Data in American Journal of Respiratory and Critical Care Medicine demonstrate ARIKAYCE’ s potential to achieve early and sustained negative sputum cultures. BRIDGEWATER, N.J., Oct. 18, 2016-- Insmed Incorporated, ...
- Reuters•21 days ago
Drugmaker Insmed Inc said on Wednesday it had bought the rights to an experimental early-stage respiratory drug from Britain's AstraZeneca Plc in a deal worth $150 million. AstraZeneca will get $30 million in upfront fees and $120 million in various milestone payments, Insmed said. The deal adds AstraZeneca's AZD7986 compound to Insmed's pipeline.
- GlobeNewswire•22 days ago
BRIDGEWATER, N.J., Oct. 05, 2016-- Insmed Incorporated, a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced a licensing agreement with AstraZeneca ...
Insmed Incorporated (INSM)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Day's Range||13.83 - 14.37|
|52wk Range||9.02 - 21.14|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-6.54|
|Avg Vol (3m)||265,307|
|Dividend & Yield||N/A (N/A)|